Boston Scientific Shares Rise on Acquisition of SoniVie in Hypertension Treatment Expansion
1min read In a significant move, boston scientific has agreed to acquire SoniVie Ltd., a private medical device company known for its TIVUS intravascular ultrasound system. This system aims to provide a novel treatment for hypertension by targeting the renal sympathetic nerves through a technique known as renal denervation (RDN). The acquisition marks an expansion of Boston Scientific's portfolio in interventional cardiology, offering new therapeutic avenues for hypertension patients who do not respond well to conventional medication.
Boston Scientific has been a strategic investor in SoniVie since 2018, holding a 10% stake. This acquisition involves a payment of approximately $360 million for the remaining 90% of the shares, with additional contingent payments of up to $180 million based on specific regulatory milestones. The transaction is expected to be finalized in the first half of 2025, further consolidating Boston Scientific’s position as a leader in innovative hypertension treatment technologies.
The TIVUS system is currently under clinical trials and leverages ultrasound energy to achieve precise renal nerve ablation without requiring direct contact with the artery wall, distinguishing it from traditional radiofrequency methods. This could profoundly impact patients who have struggled with hypertension management, offering an alternative that reduces sympathetic nerve activity and potentially stabilizing blood pressure levels.
Given the global rise in cardiovascular diseases, this acquisition could pave the way for Boston Scientific to address a critical need for alternative hypertension treatments. As more data emerges from ongoing clinical trials, the TIVUS system promises to augment traditional medication and lifestyle changes, potentially reshaping treatment paradigms in cardiovascular care.
Boston Scientific's acquisition of SoniVie highlights the strategic move towards integrating advanced technologies for better patient outcomes in the ever-evolving field of medical devices. The broader implications of this acquisition might spark intensified competition in the RDN market, as players innovate to meet the persistent demand for effective hypertension solutions.
